Expertise in
17
conditions

Dr. Jana L. Portnow

Oncology
City Of Hope Medical Foundation
209 Fair Oaks Ave, 
South Pasadena, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
17
conditions
City Of Hope Medical Foundation
209 Fair Oaks Ave, 
South Pasadena, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jana Portnow is an Oncologist in South Pasadena, California. Dr. Portnow is highly rated in 17 conditions, according to our data. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Endoscopy.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas
A Phase I Study of Multiple Doses of Neural Stem Cell-Based Oncolytic Virotherapy (NSC-CRAd-S-pk7) Administered Intracerebrally to Patients With Recurrent High-Grade Gliomas
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Procedure, Biological
Study Drug: Neural Stem Cells-expressing CRAd-S-pk7
Study Phase: Phase 1
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers
A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Biological
Study Drug: Chimeric Antigen Receptor T-Cell Therapy
Study Phase: Phase 1
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas
A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Carboxylesterase-Expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride
Study Phase: Phase 1
Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients with Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.
Safety and Imaging of Post-Operative Low Dose Versus Standard Dose Dexamethasone in Patients with Primary or Metastatic Brain Tumors: a Randomized, Double-blinded Feasibility Study.
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Dexamethasone
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors
An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Other, Procedure, Drug
Study Drug: Eribulin Mesylate
Study Phase: Early Phase 1
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
Enrollment Status: Withdrawn
Publish Date: February 16, 2023
Intervention Type: Biological
Study Drug: CYNK-001
Study Phase: Phase 1/Phase 2
Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma
Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Biological
Study Drug: Neural stem cells loaded with an oncolytic adenovirus
Study Phase: Phase 1
A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas
A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

42 Total Publications

Pharmacokinetic analysis of carboplatin and fluorescein brain permanence following ultrasound-based blood-brain barrier opening.
Pharmacokinetic analysis of carboplatin and fluorescein brain permanence following ultrasound-based blood-brain barrier opening.
Journal: medRxiv : the preprint server for health sciences
Published: February 20, 2025
Similar Doctors
Expertise in
31
conditions
Dr. Mark B. Agulnik
Oncology
Expertise in
31
conditions
Dr. Mark B. Agulnik
Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (5.1 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Agulnik is an Oncologist in Los Angeles, California. Dr. Agulnik is highly rated in 31 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Angiosarcoma, Osteotomy, and Colonoscopy.

Expertise in
22
conditions
Dr. Tanya B. Dorff
Oncology | Hematology Oncology
Expertise in
22
conditions
Dr. Tanya B. Dorff
Oncology | Hematology Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (0.1 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Dorff is an Oncologist and a Hematologist Oncology provider in South Pasadena, California. Dr. Dorff is highly rated in 22 conditions, according to our data. Her top areas of expertise are Prostate Cancer, Penile Cancer, Familial Prostate Cancer, Prostatectomy, and Penectomy.

Expertise in
17
conditions
Dr. Marwan G. Fakih
Oncology | Hematology Oncology
Expertise in
17
conditions
Dr. Marwan G. Fakih
Oncology | Hematology Oncology

City Of Hope Medical Foundation

209 Fair Oaks Ave, 
South Pasadena, CA 
 (0.1 miles away)
626-396-2900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marwan Fakih is an Oncologist and a Hematologist Oncology provider in South Pasadena, California. Dr. Fakih is highly rated in 17 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Anal Cancer, Familial Colorectal Cancer, Endoscopy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Portnow's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile